Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma

por Liu, Qingjun, Mier, James W, Panka, David J
Publicado 2011

Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma

por Liu, Qingjun, Mier, James W., Panka, David J.
Publicado 2021

Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b(+)/Gr-1(+) myeloid derived suppressor cells

por Panka, David J, Liu, Qingjun, Geissler, Andrew K, Mier, James W
Publicado 2013

Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells

por Panka, David J., Liu, Qingjun, Geissler, Andrew K., Mier, James W.
Publicado 2021

Novel drugs that target the metabolic reprogramming in renal cell cancer

por van der Mijn, Johannes C., Panka, David J., Geissler, Andrew K., Verheul, Henk. M., Mier, James W.
Publicado 2016

Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression

por Zhang, Liang, Bhasin, Manoj, Schor-Bardach, Rachel, Wang, Xiaoen, Collins, Michael P., Panka, David, Putheti, Prabhakar, Signoretti, Sabina, Alsop, David C., Libermann, Towia, Atkins, Michael B., Mier, James W., Goldberg, S. Nahum, Bhatt, Rupal S.
Publicado 2011

Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2)

por Erbe, Amy K, Wang, Wei, Kim, Kyung Mann, Carmichael, Laskeesha, Gallendberger, MIkayla, Hess, Dustin, Mendonca, Eneida A, Song, Yiqiang, Hank, Jacquelyn A, Chen, Su-Chun, Signoretti, Sabina, Atkins, Michael B, Carlson, Alexander, Mier, James, Panka, David, McDermott, David F, Sondel, Paul M
Publicado 2015

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

por Frederick, Dennie T., Salas Fragomeni, Roberto A., Schalck, Aislyn, Ferreiro-Neira, Isabel, Hoff, Taylor, Cooper, Zachary A., Haq, Rizwan, Panka, David J., Kwong, Lawrence N., Davies, Michael A., Cusack, James C., Flaherty, Keith T., Fisher, David E., Mier, James W., Wargo, Jennifer A., Sullivan, Ryan J.
Publicado 2014